01/6Oxford University-AstraZeneca vaccine launch by 2021?

Oxford University-AstraZeneca vaccine launch by 2021?

The University of Oxford-AstraZeneca backed novel coronavirus vaccine has been one of the leading vaccine candidates in the global race. The vaccine, currently in phase III of its trials, which was considered to be the first one to get launched for the public in 2020 will be most likely available for public deployment by 2021, according to latest reports.

Currently, phase III clinical trials are being conducted in research facilities across UK, US, Brazil and South Africa. Trials are also expected to start from next week in India in partnership with Serum Institute of India.

readmore

02/6Russia successfully registers 'Sputnik V' as the first COVID-19 vaccine

Russia successfully registers 'Sputnik V' as the first COVID-19 vaccine

The news follows after Russia successfully registered the world's first COVID-19 vaccine, 'Sputnik V' after claiming decent results post completion of phase I. Russian authorities plan to scale up production and have millions of doses ready before the year-end.

readmore

03/6Oxford-AstraZeneca vaccine is one of the top candidates in the race

Oxford-AstraZeneca vaccine is one of the top candidates in the race

The Oxford University backed vaccine, called AZD-12222 was one of the first to head into the human trial stage as well as start late-stage trials. It's also one vaccine, which has found to be "safest" yet by the WHO in the pre-development phase.


Made using a non-replicating viral strain, the most recent development was confirmed by researchers from the Oxford vaccine research institute, quelling any rumours about an early advent related to launching in 2020.


With researchers hopeful of seeing the end of clinical trials by November of early December, Oxford Researchers have also signed an agreement with Mexico and Argentine authorities to scale up production in the first quarter of 2021.

readmore

04/6Status of Oxford vaccine trials in India

Status of Oxford vaccine trials in India

The announcement also comes after SII head, Adar Poonawallah announced the availability of the vaccine for Indian masses by 2020. In an interview with a media agency recently, he spoke at length, saying:


"We are going to start trials in less than two weeks. The trial is in partnership with ICMR. We will start manufacturing vaccines by the end of August."


According to revised proposals, the vaccine under the offering, which will be sold and marketed as 'Covishield' in India, will involve candidates from a healthy age-group. SII will recruit 1,600 people above 18 years of age will participate in early trials, which will now be spread across 17 sites, which will include centres like All India Institute of Medical Sciences, Delhi, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS in Jodhpur, Nehru Hospital in Gorakhpur, and JSS Academy of Higher Education and Research in Mysore.

readmore

05/6Is 2020 too early to have a vaccine ready?

Is 2020 too early to have a vaccine ready?

Oxford's most recent announcement may make it a bit harder for the world to get a vaccine this early but makes it a bit safer than the others. Russian vaccine's early launch, for example, has been marred by controversies and safety concerns.

readmore

06/6Making the vaccine available for all

Making the vaccine available for all

The University of Oxford has also signed pacts with global vaccine makers and vaccine federations. WHO also asked top vaccine makers in the race to be a part of its global vaccine alliance, COVAX to ensure equal distribution of the doses for the public.


Pune-based Serum Institute of India (SII), will also be producing millions of doses for the company. Serum Institute will also be receiving close to $150 million 'at-risk' funding from Bill and Melinda Gates Foundation to develop a low-cost, readily available doses for populations at large. The funding will be routed through GAVI, international vaccine alliance and will help the vaccine producer overcome problems pertaining to marketing, production and pricing on the global level.

readmore